Abbott Laboratories agreed to resolve part of litigation over its specialty formulas for preterm infants for approximately $670 million. The deal reduces legal overhang but implies a substantial cash outlay. Overall news is negative-cautious for ABT as it points to continued litigation cost risk.
Abbott Laboratories agreed to resolve part of litigation over its specialty formulas for preterm infants for approximately $670 million. The deal reduces legal overhang but implies a substantial cash outlay. Overall news is negative-cautious for ABT as it points to continued litigation cost risk.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
